Posoleucel is under clinical development by AlloVir and currently in Phase III for Cytomegalovirus (HHV-5) Infections. According to GlobalData, Phase III drugs for Cytomegalovirus (HHV-5) Infections have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Posoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Posoleucel overview

Posoleucel (ALVR-105) is under development for the prophylaxis and treatment of hematopoietic stem cell transplant-associated viral infections such as refractory cytomegalovirus infection (CMV), adenovirus infection, Epstein–Barr virus infection, human herpesvirus 6 infection, hemorrhagic cystitis, BK virus infection, polyomavirus Infections (JC virus), and multi-virus infections. The drug candidate is an allogeneic, off-the-shelf multi-virus specific T-cell therapy, administered through intravenous injection and infusion. It was also under development for the prophylaxis and treatment of solid organ transplant (SOT) associated infections such as nephritis (BK-nephritis) and viral infections associated with primary immunodeficiency disorder.

AlloVir overview

AlloVir, formerly ViraCyte, develops and delivers novel cell therapies to restore natural T-cell immunity for the treatment of patients suffering from life-threatening virus-associated diseases. The company is a global leader in the development of VST immunotherapies. The company lead pipeline candidate is Viralym-M (ALVR105) targeting Cytomegalovirus (CMV), Adenovirus (AdV), BK Virus (BKV), Human Herpesvirus-6 (HHV-6) and Epstein-Barr (EBV). Other pipeline candidates include ALVR106 for the treatment of Influenza, Parainfluenza Virus (PIV), Respiratory syncytial virus (RSV), and Human Metapneumovirus (hMPV); ALVR109 for COVID-19; ALVR107 for Hepatitis B; and ALVR108 for Human Herpesvirus-8 (HHV-8). The company is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Posoleucel’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.